研究动态
Articles below are published ahead of final publication in an issue. Please cite articles in the following format: authors, (year), title, journal, DOI.

肝内胆管癌患者的预后因素。

Prognostic factors in patients with intrahepatic cholangiocarcinoma.

发表日期:2024 Aug 17
作者: Yun-Jau Chang, Yao-Jen Chang, Li-Ju Chen
来源: Disease Models & Mechanisms

摘要:

肝内胆管癌(ICC)是台湾第二常见的肝脏恶性肿瘤,也是台湾最致命的癌症之一。诊断 ICC 后生存率仍然很低。本研究旨在探讨 ICC 患者的生存和预后因素。 2004 年至 2018 年期间新诊断 ICC 的所有患者均从国家癌症数据库中确定,并随访至 2020 年 12 月。使用 Kaplan-Meier 方法和 Cox 比例风险模型进行总生存期 (OS) 估计。计算了 95% 置信区间的风险比。最初,7940 名 ICC 疾病患者(IV 期:55.6%,4418/7940)符合本研究的资格。只有 32.3%(2563/7940)的 ICC 患者接受了肝切除术。经过倾向评分匹配后,匹配并选择了 969 对 (N = 1938) 患者(平均年龄 62.8±11.0 岁,53.1% 为男性,29.7% 患有肝硬化)。中位随访时间为 80.0 个月(范围 25-201 个月)。手术组3年、5年OS率分别为44.0%、36.4%,非手术组分别为26.0%、23.7%。手术、年轻患者(≤54 岁)、肿瘤尺寸小、无血管侵犯和化疗与 I-III 期疾病患者更好的 OS 相关。手术获益在 I 期疾病中最大,其次是 II 期。在 IV 期疾病患者中,手术、年轻患者(≤64 岁)、单一肿瘤和无血管侵犯等因素与更好的 OS 相关。化疗与更好的 OS 无关。 ICC 患者的长期生存率非常差。与非手术患者相比,手术患者的 3 年和 5 年 OS 率分别提高约 18% 和 12%。早期发现和手术干预可以显着改善 ICC 患者的 OS。© 2024。作者。
Intrahepatic cholangiocarcinoma (ICC) is the second commonly-seen liver malignancy and one of the most fatal cancers in Taiwan. Survival after diagnosis of ICC remains poor. This study aimed to investigate the survival and prognostic factors in patients with ICC. All patients with newly diagnosed ICC during 2004 to 2018 were identified from a national cancer database and followed until December 2020. Estimates of overall survival (OS) were conducted using the Kaplan-Meier method and Cox proportional hazards model. Hazard ratios with 95% confidence intervals were calculated. Initially, 7940 patients with ICC disease (stage IV: 55.6%, 4418/7940) were eligible for this study. Only 32.3% (2563/7940) patients with ICC underwent liver resection. After Propensity score matching, 969 pairs (N = 1938) of patients were matched and selected (mean age 62.8 ± 11.0 years, 53.1% were male, 29.7% had cirrhosis). The median follow-up time was 80.0 months (range 25-201 months). The 3-, 5-year OS rates were 44.0%, 36.4% in the surgical group and 26.0%, 23.7% in the non-surgical group, respectively. Surgery, young patients (≤ 54 years), small tumor size, no vascular invasion and chemotherapy were associated with better OS in patients with stages I-III disease. Surgery benefit was maximum in stage I disease followed by stage II. In patients with stage IV disease, factors such as surgery, young patients (≤ 64 years), single tumor, and no vascular invasion were associated with better OS. Chemotherapy was insignificantly associated with better OS. Long-term survival in patients with ICC is very poor. Compared to non-surgical patients, surgery conveys approximately 18% and 12% better OS rates at 3-year and 5-year, respectively. Early detection and surgical intervention may improve OS substantially in patients with ICC.© 2024. The Author(s).